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The melanocortin system comprises of melanocortin peptides; α-, β- and γ- 
melanocortin stimulating hormones (MSH) and adrenocorticotropic hormone 
(ACTH) derived from the proteolytic degradation of pro-opiomelanocortin 
(POMC) prohormone. These hormones regulate important physiological 
processes such as skin pigmentation, energy expenditure and food intake as 
well as exocrine and inflammatory activities amongst other functions. Biological 
activities of melanocortins occur via the activation of five melanocortin receptors 
(MC1 – MC5). MC1 receptor is activated by α-MSH and plays an important role 
in inflammatory activities. Recent studies revealed that the activation of MC1-R 
in macrophages reduces cholesterol uptake and promotes cholesterol efflux. 
Against this background, we hypothesised that MC1-R deficiency leads to 
decreased expression of reverse cholesterol transport (RCT) genes and 
consequently, impact the process of RCT. In this study, we investigated the 
transcriptional regulation of cholesterol transporter genes (ABCA1, ABCG1, 
ABCG5, ABCG8, SR-B1, SR-A1 and CD36) in wild type (WT) and MC1 
receptor deficient (MC1-Re/e) mice on ApoE knockout background as well as the 
effect of high fat diet (4 weeks) in the two genotypes. The RNA from aorta, liver, 
spleen and bone marrow of the mice was extracted, converted to cDNA and 
then quantified with real-time polymerase chain reaction (qPCR) for the 
selected genes. We also conducted in vivo cholesterol efflux assay by loading 
tritiated cholesterol into bone marrow-derived macrophages and 
intraperitoneally injected them into WT and MC1-Re/e mice. Twenty-four to forty-
eight hours after the injection, radioactivity accumulation of H3-cholesterol in the 
plasma, liver and feces was measured. We observed that crucial cholesterol 
transporter genes; ABCA1 and ABCG1 were downregulated in the aorta of 
MC1-Re/e mice, ABCG5 and ABCG8 expression in the liver of this group of mice 
were also reduced, an effect exacerbated by diet rich-in high fat. Generally, the 
cytokines and adhesion molecules (IL-1β, IL-6, CCL-2, CD62P etc.) analysed 
from the aorta of the MC1-Re/e mice were significantly reduced compared to WT 
mice. The cholesterol efflux assay showed no major differences between the 
genotypes in terms of cholesterol efflux capacity. In conclusion, MC1-R 
deficiency in ApoE knockout mice resulted in reduced expression of RCT genes 
particularly in the aorta and liver, which might hamper the efficiency of RCT 
process. 
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1.  INTRODUCTION 
1.1 Cardiovascular Disease and Atherosclerosis 
Cardiovascular diseases (CVDs) are classes of disorders that affect the heart 
and blood vessels. It has been the leading cause of death over the past decade 
especially, ischaemic heart disease (IHD) and stroke. The development of 
CVDs can be genetically linked or as a result of infection. However, 
environmental factors such as increased intake of saturated fat and sedentary 
life style constitute a higher influence in the development of these conditions. In 
2012, 31% (17.5 million people) of global mortality was caused by 
cardiovascular complications.  IHD claimed 7.4 million people lives and 6.7 
million deaths were associated with stroke. Thus, CVDs are the number one 
cause of death worldwide (WHO, 2016). In Europe, CVDs account for 4 million 
deaths each year. A prominent risk factor for the development of CVD is the 
luminal narrowing of the major arteries that supply blood to the brain (stroke), 
the heart (CHD - coronary heart disease) and the lower extremities (PVD - 
peripheral vascular disease). Stroke and myocardial infarction (heart attack) are 
the two main acute cardiovascular events that restrict blood flow to the brain 
and heart. This mostly stems from the build-up of fat deposits within the walls of 
the blood vessels – a process called atherosclerosis.  
Atherosclerosis is one of the most common CVDs. It is currently recognised as 
a chronic inflammatory disease characterised by the narrowing of the lumen of 
arteries with fatty material, that eventually cause plaque (atheroma) build-up. 
Consequently, thrombosis ensues and the obstruction of blood supply to vital 
organs. The atheroma in atherosclerosis disease is a lipoprotein-driven 
condition and results in intimal inflammation, calcification, fibrosis and necrosis. 
The plaques also contain cellular debris as well as hydroxyapatite (calcium 
deposits), which in addition to the fatty deposits are very thrombogenic. Under 
stable conditions, the atheroma plaques are protected from the circulating blood 
by a thick fibrous cap made up of extracellular matrix proteins (e.g. collagen) 
and vascular smooth muscle cells (Libby et al; 2011). The fibrous cap may be 
degraded by zinc-dependent matrix metalloproteinases (MMPs) enzymes 
secreted by macrophages, which increases the risk of plaque rupture.  
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MMPs may also be responsible for the degradation of elastic laminae present in 
the layers of the arterial wall, thereby promoting the migration of cells of the 
smooth muscle from the tunica media to the fibrous cap and consequently, 
strengthening the plaque. A plaque can be characterised as stable or unstable 
based on the thickness of the fibrous cap and size of the lipid core. A stable 
plaque is less likely to rupture and it consists of fibrous cap rich in thick smooth 
muscle-cells with a small inner lipid core. On the other hand, vulnerable or 
unstable plaques with high susceptibility of rupturing contain large necrotic lipid 
core and thin fibrous cap (Fig. 1). A defective fibrous cap increases the risk of 
exposing the thrombogenic content of the plaque to the circulating blood – 
thrombosis. A large percentage of plaque ruptures is clinically silent and a very 
small fraction actuates stroke and myocardial infarction (Libby et al; 2011).  
 
 
Fig. 1 Stages of atherosclerotic lesion development (Adapted from Libby et al; 2011) 
 
The actual cause of atherosclerosis is unknown, but it is preceded by an initial 
process known as atherogenesis – a disorder of the arterial wall. 
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 The cellular components of atherosclerosis include intimal smooth muscle 
cells, endothelial cells and leukocytes. These are major players in the 
development of this chronic immunoinflammatory disease of medium and large-
sized arteries laden by lipid. Atherosclerotic lesion is initiated when the 
endothelium becomes leaky and dysfunctional, which may encourage the 
adherence of platelets, plasma and lipoprotein particles (Davies et al; 1988). 
Here, the trapped lipoprotein particles are oxidised into pro-inflammatory, pro-
atherogenic, cytotoxic and chemotaxic entity, of which the pathophysiology is 
not fully understood yet. The process of atherogenesis involves the 
transmigration of monocytes via the endothelium into the intima layer of the 
arterial wall where they differentiate mainly into macrophages. These cells 
scavenge for modified lipoproteins such as oxidised low-density lipoprotein 
(oxLDL) turning them eventually into lipid-rich foam cells. The uptake of 
cholesterol by macrophages is facilitated by the expression of scavenger 
receptors such as CD36/FAT (fatty acid translocate) and SR-A1 (scavenger 
receptor class A type 1). The transmigration process is promoted by inflamed 
endothelial cells expressing high levels of adhesion molecules. Foam cells 
within the plaque aggravate inflammatory response mediated by the release of 
chemokines and growth factors and may undergo apoptosis (Tall and  Yvan-
Charvet, 2015).  
As a result, the endothelium is activated by these stimuli and adhesion 
molecules such as vascular cell adhesion molecule-1 (VCAM-1) are 
upregulated in addition to T-cell and monocyte recruitment. Other activated 
adhesion molecules during this process are P-selectin, intercellular adhesion 
molecule-1 (ICAM-1) and E-selectin, that are capable of luring blood cells into 
the lesion.  Transendothelial migration of blood-borne cells (monocytes and T-
lymphocytes) to the atherosclerotic lesion also requires chemotactic cytokines 
(atherogenic chemoattractants) – chemokine ligand 2 (CCL-2) and oxLDL 
(Libby Peter, 2002). Monocyte derived macrophages within the intima are 
capable of recruiting themselves by secreting CCL-2. Many pro-atherogenic 
cytokines such as interleukin-1 (IL-1) and interleukin-6 (IL-6) are upregulated in 
atherosclerotic plaques.  
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Targeting the receptors of these cytokines could help hinder the inflammatory 
process associated with this disease and also remove the necrotic foam cells in 
the plaque.  
Today, it is crucial for cardiovascular researchers to explore the inherent 
pathology of atherosclerosis in order to better understand the pathophysiology 
of this disease and eventually, identify potential therapeutic targets.  
1.2 Cholesterol and Cholesterol Carriers 
Cholesterol is synthesised by the liver and can also be ingested from food. The 
body cells require cholesterol for their functioning, for example, in cell 
membrane formation and it is also an essential material for the synthesis of 
steroid hormones, bile and vitamin. Cholesterol molecules are packaged and 
carried by lipoproteins. Lipoproteins are small singe-layer phospholipid 
membrane particles made up of fat, protein and cholesterol. Plasma lipoproteins 
include; high-density lipoprotein (HDL), low-density lipoprotein (LDL), 
intermediate-density lipoprotein (IDL), very low density lipoprotein (VLDL) and 
chylomicrons, which facilitate the movement of fat and cholesterol via the 
bloodstream. These cholesterol-carriers contain different proportion of 
triglycerides, cholesterol and also differ by density. The lower the density of the 
lipoprotein, the higher is the fat content within it. The level of cholesterol in the 
cells must be managed within a narrow limit. An excess or too little cellular 
cholesterol could disrupt the cell membrane and/or causes necrosis and 
apoptosis (Tabas Ira, 2002). Cells can obtain the required cholesterol from 
lipoproteins in the plasma and from intracellular synthesis thus, cholesterol 
deficiency in cells is a rare occurrence. However, excess systemic cholesterol is 
a common phenomenon. Since cells are not able to degrade cholesterol, with 
the exception of adrenocortical cells and hepatocytes, reduction of cellular 
cholesterol content is either via cholesterol efflux or conversion of cholesterol to 
cholesteryl esters. The latter though, can also be toxic when cells are 
overloaded with cholesterol, unlike cholesterol efflux (Low et al; 2012).   
Increased blood cholesterol level puts an individual in high risk of heart and 
circulatory diseases. This has no obvious symptoms, but the individual has a 
marked risk of developing conditions such as atherosclerosis, heart attack, 
stroke and other CVDs.  
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A simple blood test (lipoprotein panel) could help identify people at high risk of 
developing coronary heart disease by measuring total body cholesterol, LDL, 
HDL and triglycerides levels (NIH Medline Plus, 2012). The table below (Table 
1) shows the desirable levels of total cholesterol and its fractions. 
Desirable Cholesterol Level 
Total Cholesterol < 200 mg/dL   < 4.0 mmol/L 
LDL < 100 mg/dL   < 3.0 mmol/L 
HDL               ≥  60 mg/dL              ≥ 1.5 mmol/L 
Triglycerides < 150 mg/dL   < 3.0 mmol/L 
Table 1 Desirable blood cholesterol level (Adapted from NIH Publication No. 01 – 3670 and HEART UK) 
A raised and unhealthy pattern of cholesterol noticed in some individual 
generally depends on both controllable and uncontrollable factors. Excess 
consumption of diet enriched in saturated fat and cholesterol, in addition to 
being overweight, and idle lifestyle contribute to the controllable risk factors of 
heightened blood cholesterol level. Physical exercises and loosing excessive 
body weight help to lower the circulating levels of total cholesterol, LDL-C and 
triglycerides. In return, the level of HDL is raised. On the other hand, age, 
gender, heredity, medical history and ethnicity may predispose certain 
individuals to higher blood cholesterol. These elements are uncontrollable risk 
factors, which may subsequently contribute to the development of circulatory 
and heart diseases. 
Also, impairment in the fat and cholesterol transportation may pose a major 
health consequence.  Such malfunction could increase the concentration of LDL 
in blood and provoke atherogenesis. Ideally, the ratio of LDL to HDL should be 
low. There is a correlation between heart diseases and high level of LDL (“bad 
cholesterol”). The risk of developing a CVD increases when LDL particles 
become oxidised following the invasion of endothelial lining of blood vessels. 
Over time, the rate of atherosclerosis development increases on the arterial 
walls as they attract macrophages. The so-called “good cholesterol” (HDL) 
helps to alleviate the occurrence of atherosclerosis, if in higher concentration in 
the blood. HDL transportation of fat molecules away from artery walls prevents 
or reduces the progression of atherosclerosis.  
6 
 
While apolipoprotein A (ApoA) serve as the major protein component of HDL, 
apolipoprotein B (ApoB) is the primary apolipoprotein of 
chylomicrons, VLDL, IDL and LDL particles (Wasan et al; 2008). An important 
lipoprotein in the modelling of atherosclerosis in mice is the apolipoprotein E 
(ApoE). ApoE is found on the surface of most lipoprotein particles, which play a 
vital role in the clearance of triglycerides and cholesterol from the blood. It is 
mainly produced by the liver and macrophages and it is essential in the 
metabolism of cholesterol as well as transportation of lipoprotein, cholesterol 
and fat-soluble vitamins to the lymph system, then into the blood (Baars et al; 
2011). The role of ApoE in atherosclerosis development has been ascertained 
in a gene knock-out mouse model, namely in ApoE-/- mice. It interacts with LDL 
receptor family and heparan sulfate proteoglycans to enhance lipoprotein 
metabolism. ApoE is an important molecule in the onset of atherosclerosis in 
the coronary arteries since it plays a role in reverse cholesterol transport (RCT) 
process, when it influence the ability of HDL particles in mediating efflux of lipid 
from cells (Davignon et al; 1988).  Hypercholesterolaemia and extensive 
atherosclerotic lesions development are usually observed in ApoE-/- mice even 
when on a chow diet. These characteristics of ApoE knockout mice are more 
pronounced when put on a western (high fat) diet. This is a result of impaired 
clearance of chylomicrons and VLDL. Consequently, increased plasma 
triglycerides and cholesterol ensue in addition to the development of substantial 
amount of atherosclerotic lesions (Jawien J, 2012). 
1.3 Cholesterol Efflux and Reverse Cholesterol Transporters 
Cholesterol and triglycerides are important part of the body physiology. These 
are key components of cellular structure and function. Hypercholesterolaemia 
however, enhances cholesterol accumulation in monocyte-derived 
macrophages and other leukocytes, which in turn, promotes inflammatory 
responses such as augmentation of Toll-like receptor (TLR) signaling, activation 
of inflammasome and the secretion of neutrophils and monocytes in the spleen 
and bone marrow. The activation of TLR signaling results in decreased 
cholesterol efflux, consequently increasing cholesterol accumulation and 
escalates inflammatory responses (Tall and  Yvan-Charvet, 2015).  
On the arterial wall, the cholesterol contained in the cholesterol laden 
macrophages is the main inflammatory driver in atheroma build-up.  
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This cholesterol is eventually efflux from the macrophage primarily by ATP-
binding cassette transporters such as ABCA1 and ABCG1. These cholesterol 
transporters initiate the process of RCT via the enhancement of cholesterol 
efflux from macrophages to ApoA-I and HDL. Cholesterol transported to the 
liver are either recycled into lipoprotein or further excreted into bile through 
ABCG5 and ABCG8 transporters.   
HDL is thought to be an anti-atherogenic lipoprotein since it is inversely linked 
with the risk of atherosclerosis development. The anti-atherogenic functions of 
HDL are due to its ability to intrinsically transport proteins, anti-oxidant capacity, 
anti-coagulative, anti-inflammatory and nitric oxide-promoting properties, as well 
as mediation of macrophage cholesterol efflux. HDL assist in the maintenance 
of net cholesterol concentration in the arterial wall as it readily accepts 
cholesterol from cholesterol-rich macrophages thereby, alleviating pro-
inflammatory responses (Rosenson et al; 2011). HDL confers protection against 
the induction of atherosclerosis by promoting the efflux of cholesterol from 
macrophages via liver, bile and feces - a mechanism known as RCT. This 
process involves cholesterol transportation from peripheral tissues and 
macrophages via plasma HDL to the liver for ultimate fecal excretion (Fig. 2). 
The concentration of cholesterol in HDL is proportional to the efficiency of RCT 
process. A critical starting step of RCT involves the efflux of cholesterol from 
macrophages to plasma HDL particles. An important pathway for this process 
includes the interaction between cholesterol-deficient ApoA-I complexes and 
ABCA1. This is followed by ABCG1 mediating the interaction of cholesterol 
efflux from macrophage with cholesterol-containing α-HDL particles (Timmins et 
al; 2005). On the other hand, the scavenger receptor class B type I (SR-BI) 
mediates bidirectional lipid transportation in the macrophage. And, this is 
dependent on the content of cholesterol in the lipid-containing macrophages. 
However, SR-BI is more prominent in cholesterol trafficking by the liver via 
selective uptake of cholesteryl esters from mature HDL.   
In the liver, strolin-1 and strolin-2 proteins encoded by ABCG5 and ABCG8 
respectively facilitate the biliary excretion of dietary sterol (cholesterol) (Peter et 
al; 2011). 
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Fig. 2 Reverse cholesterol transportation (RCT) (Adapted from Cynthia Hong and Peter Tontonoz; 2014) 
 1.4 Melanocortins and the Melanocortin System 
The melanocortin system is involved in diverse physiological functions including 
energy homeostasis, sexual function, pigmentation, exocrine function, pain 
relief, steroidogenesis, cardiovascular regulation, temperature regulation, 
immunomodulation, neuromuscular regeneration and inflammation (Catania et 
al; 2004). Genetics studies and knockout mouse models have further elucidated 
the role of melanocortins in inflammation regulation (Hetal et al; 2011). This 
family of peptides are derived from propopiomelanocortin (POMC) prohormone 
and are expressed in the central nervous system as well as in the peripheral 
tissues. They consist of adrenocorticotropic hormone (ACTH) and α-, β-, and γ-
melanocyte-stimulating hormone (α-, β-, γ-MSH). Melanocortin peptides have 
affinity for five melanocortin receptors (MCRs), which are G-protein coupled and 
stimulate cAMP pathway through stimulatory Gs protein and adenylate cyclase 
(Fig. 3).  
The affinities for MCRs by melanocortins differ. MCR activation is also 
associated with inositol trisphosphate (IP3), MAP Kinase, extracellular Ca
2+ 
influx, phosphokinase C (PKC) and Janus kinase pathway (Kapas et al; 1995). 
Melanocortin-1 (MC1-R) and melanocortin-3 (MC3-R) receptors are particularly 
involved in the inflammatory process.  
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MCRs regulate inflammation by hindering the activation of leukocytes to the 
atherogenic site in the artery. Macrophages express melanocortins and their 
receptors, namely MC1-R and MC3-R are functionally active on these cells 
(Hetal et al; 2011). Extensive experimental and clinical investigation on these 
MCR subtypes shows that their activation, especially that of MC1-R, has a 
strong potential for the management of inflammatory disorders (Catania et al; 
2004, Rinne et al; 2015, Rinne et al; 2017). MC1-R is expressed by a variety of 
leukocytes such as monocytes and macrophages and by other cells involved in 
the pathophysiology of atherosclerosis. The activation of MC1-R inhibits the 
action of pro-inflammatory molecules such as IL-1, nitric oxide, IL-6, TNF-α, 
CCL-2 and INFγ via the modulation of NF-κB transcription factor (Ira and Tung, 
2003).  
(a)
(b)
(c)
 
Fig. 3 (a) the melanocortin system (b) melanocortin 7-TM (GPCR) receptor (c) MC1-R activation & 
deficiency 
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α-MSH secreted by macrophages possesses anti-inflammatory properties via 
counteracting the effect of pro-inflammatory cytokines, nitric oxide and 
chemokines. MCR activation in macrophages inhibits leukocyte 
chemoattraction, induce expression of heme oxygenase-1 and increases 
phagocytosis and efferocytosis (Hetal et al; 2011). In a recent studies by Rinne 
et al, MC1-R deficiency was directly linked to increased arterial stiffness and 
impaired endothelial function (Rinne et al; 2015). Furthermore, a previous study 
by this group concluded, that the activation of melanocortin receptor is effective 
in the limitation of plaque inflammation and improved arterial function in 
atherosclerotic mice (Rinne et al; 2014).  
Interestingly, a recent investigation revealed that MC1-R agonist activation in 
macrophages reduces oxLDL uptake via the down regulation of CD36 cell 
surface expression and increases ABCA1 and ABCG1 expression, thereby 
promoting RCT (Rinne et al; 2017). The link between melanocortin biology and 
atherosclerosis development in mice is a relatively new area of the disease. In 
this Master’s thesis, we will further investigate the relationship between MC1-R 
and cholesterol transporter genes in atherosclerotic mouse model. Specifically, 
we aim to study how MC1-R deficiency affects the expression of cholesterol 
transporter genes in atherosclerotic ApoE-/- mice. Furthermore, we will explore 
whether there is a functional consequence of MC1-R deficiency in terms of in 
vivo reverse cholesterol transportation. We hypothesise that MC1-R deficiency 
leads to decreased expression of reverse cholesterol transportation genes and 
consequently, impact the efflux of cholesterol from monocyte-derived 
macrophages and the process of RCT. 
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2.  RESULTS 
2.1 ABCA1 and ABCG1 Cholesterol Transporters are Down-
regulated in the Aorta of MC1-R Deficient Mice 
 
C57BL/6J mice of ApoE-/- background were divided into two experimental 
groups; chow diet fed mice and four weeks western diet group of mice. Each 
group of mice contained two genotypes subgroups; ApoE-/- wild type (WT) black 
mice and yellow ApoE-/- MC1-Re/e mice. Tissue samples (20mg - 50mg) with 
high relevance to the pathogenesis of atherosclerosis (aorta, liver, spleen and 
bone marrow) were obtained from these mice after sacrifice. RNA extraction 
was carried out with QIAGEN RNA kit and reverse transcribed to cDNA (Takara 
cDNA synthesis kit). Finally, the expression of cholesterol transporter genes 
such as ABCA1, ABCG1, and CD36, SR-A1; cytokines such as  IL-1β, IL-6, 
CCL-2; stability genes Col2A1, Col3A1, αSMA etc; and other tissue-specific 
cholesterol transporters were quantified by quantitative PCR (qPCR). The 
expression of target protein was normalised to S29 and β-actin or hypoxanthine 
phosphoribosyltransferase (HPRT). ΔCt comparative method was used to 
calculate the fold induction and were presented as relative transcript levels (2-
ΔΔCt). 
Table 2: Gene Expression in the Aorta of Mice 
Gene 
Chow  4 Weeks High Fat Diet (HFD) 
 
WT 
 
MC1-R
 e/e
 
  
WT 
 
MC1-R
 e/e
 
ABCA1 1.06 ±0.15 0.69 ±0.14  1.86 ±0.18 1.47  ±0.19 
ABCG1 1.23 ±0.36 0.56 ±0.05  2.33 ±0.24 1.51 ±0.28 
CD36 1.44 ±0.62 1.76 ±0.75  3.82 ±0.76 2.55 ±0.60 
SRA-1 1.27 ±0.45 0.87 ±0.13  1.29 ±0.14 4.65 ±3.68 
SRB-1 1.09 ±0.19 1.00 ±0.32  2.28 ±0.87 1.24 ±0.25 
IL-6 2.71 ±1.62 1.80 ±0.78  5.65  ±1.81 4.46 ±2.46 
IL-1β 1.23 ±0.29 0.42 ±0.07  3.26 ±1.01 1.34 ±0.34 
CCL-2 1.42 ±0.36 0.47 ±0.19  2.33 ±0.69 0.71 ±0.20 
CCL-5 1.13 ±0.20 1.51 ±0.19  1.72 ±0.55 1.53 ±0.35 
VCAM-1 1.03 ±0.09 0.89  ±0.16  1.28 ±0.25 1.41 ±0.20 
αSMA 1.50 ±0.49 1.31 ±0.50  1.53 ±0.32 0.90 ±0.10 
12 
 
COL1A2 1.05 ±0.13 1.28 ±0.17  0.52 ±0.09 0.76 ±0.15 
COL3A1 1.10 ±0.19 0.72 ±0.07  1.46 ±0.22 0.93 ±0.14 
COL1A1 1.11 ±0.21 1.25 ±0.31  0.94 ±0.29 0.62 ±0.11 
COL4A1 1.04 ±0.11 1.14 ±0.12  0.94 ±0.12 1.02 ±0.15 
MMP2 1.58 ±0.65 1.09 ±0.45  2.08 ±0.56 2.62 ±0.98 
TGFβ1 1.01 ±0.06 1.23 ±0.14  1.13 ±0.11 1.54 ±0.16 
ARG1 0.80 ±0.67 0.73 ±0.50  0.35 ±0.18 0.34 ±0.16 
CD206 1.05 ±0.11 1.01 ±0.11  0.99 ±0.21 1.12 ±0.37 
CX3CR1 1.10 ±0.17 0.63 ±0.05  2.09 ±0.44 1.05 ±0.25 
ICAM1 1.18 ±0.28 0.82 ±0.11  0.55 ±0.09 0.68 ±0.12 
PECAM1 1.12 ±0.18 0.98 ±0.15  1.10 ±0.21 1.34 ±0.21 
CD62P 1.10 ±0.20 0.76 ±0.10  2.14 ±0.35 1.27 ±0.20 
Fold change of genes expression (Mean ±S.E.M) in aorta of ApoE KO WT and MC1Re/e mice against the housekeeping 
genes (Geo.mean S29 & HPRT).   
 
 
In the aorta, the ABCA1 and ABCG1 expression conspicuously differ in the 
genotypes as well as between the diet groups (Fig.4a & b). MC1-Re/e mice 
show reduced amount of ABCA1 and ABCG1 expression in relation to the 
ApoE-/- wild type. These cholesterol carriers are chiefly expressed by 
macrophages and play a crucial role in cholesterol homeostasis, translocating 
cholesterol out of macrophages to HDL and ApoA-I. ABCA1 and ABCG1 
reduced expression in MC1-Re/e mice may influence cholesterol efflux in this 
group of mice and impact ABCA1- and ABCG1-mediated RCT. On the other 
hand, expression of CD36 did not indicate a significant difference between the 
genotypes (Fig.4c). The scavenger receptors facilitate the influx of oxLDL when 
expressed on the surface of macrophages.  
Furthermore, collagenase type 3A1 and α-smooth muscle actin (αSMA) mRNA 
expression were down regulated in the aorta of MC1-Re/e mice (Fig. 4d & e). 
These genes play a vital role in the structure and stability of the aortic wall. The 
characteristics of plaque formed in MC1-R deficient mice may thus be less 
stable to the constant flow of blood at higher pressure within the artery.   
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Fig 4: Cholesterol Transporter and Stability Genes mRNA Expression in the Aorta 
Cholesterol transporter and stability genes mRNA expression in the aorta of WT and MC1Re/e mice fed 
with chow and 4wks HFD. (a) ABCA1 expression in aorta of chow and HFD mice. (b) ABCG1 expression 
level in aorta of the mice (c) Expression of CD36 mRNA in chow and HFD mice. (d) Col3A1 expression in 
chow and HFD mice. (e) aSMA mRNA expression. 
Gene expression was measured with qPCR and the data (fold change) is a quantity of the expressed 
mRNA.. (*P < 0.05, **P< 0.01 against WT); (###P < 0.001, ####P < 0.0001 = dietary significance); n=8 per 
group. 
 
 
The expression of cytokines, chemokines and adhesion molecules in the aorta 
of the mice was reduced in both diet groups and in MC1-R deficient genotype 
relatively to their ApoE-/- WT. Specifically, IL-1β, CCL-2, IL-6 and CD62P genes 
were down-regulated in MC1-R deficient mice (Fig.5a, b, c & d). However, an 
upregulation of TGB-1 mRNA was observed.  
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On the other hand, cytokines, chemokines and stability genes such as CD206, 
CCL-2, CCL-5, VCAM-1, ICAM1, PECAM1, Col1A1, Col1A2, Col1A4, MMP2 
and ARG1 expression in the aorta did not show significant difference between 
the two genotypes (Table 2).  
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Fig. 5: Cytokines, Adhesion Molecules and Chemokines Gene Expression in Aorta 
Cytokines, adhesion molecules and chemokines gene expression in aorta of chow and 4wks HFD mice. 
(a) IL-1β  mRNA expression level in  aorta of chow and HFD mice (b) CCL-2 expressed in aorta of chow 
and 4weeks HFD mice (c) CD62P level detected in the aorta of chow and HFD mice (d) IL-6 quantification 
in aorta of chow and 4 weeks HFD fed mice. (e)TGFβ-1 expression in aorta of chow and HFD fed mice.  
(*P < 0.05, **P< 0.01 against WT); (#P < 0.05, ##P < 0.01 = dietary significance); n=8 per group. 
 
 
 
 
 
 
15 
 
2.2 Deficiency in MC1-R Resulted in Reduced ABCG5 and ABCG8 
Expression in the Liver of HFD-fed Mice  
 
ABCG5 and ABCG8 cholesterol transporters are the primary carriers of 
cholesterol delivered to the liver for bio-degradation in the bile. These 
cholesterol carriers were downregulated in MC1-Re/e mice, as the animals’ 
system became over loaded with cholesterol from the 4 weeks western diet 
(Fig.6a & b). In the chow diet fed mice, the liver expression of ABCG5 and 
ABCG8 transporter genes were somewhat equal in both genotypes (Fig 6a & 
b). The SR-B1 scavenger receptors expressed on the surface of the liver, which 
facilitates the intake of cholesterol delivered by HDL did not show major 
difference between the genotypes or diet groups (Table 3).  
Table 3: Gene Expression of Cholesterol Transporter Genes in the Liver of Mice 
Gene 
Chow  High Fat Diet (HFD) 
 
WT 
 
MC1-R
 e/e
 
  
WT 
 
MC1-R
 e/e
 
ABCA1 1.02 ±0.05 0.97 ±0.04  0.95 ±0.04 0.94 ±0.08 
ABCG1 1.01 ±0.06 1.34 ±0.12  2.27 ±0.20 3.21 ±0.50 
CD36 1.11 ±0.21 1.56 ±0.33  5.43 ±0.69 6.42 ±0.96 
SRA-1 1.03 ±0.10 1.24 ±0.06  1.93 ±0.15 2.13 ±0.26 
SRB-1 1.01 ±0.04 0.99 ±0.07  1.17 ±0.11 1.27 ±0.09 
ABCG5 1.08 ±0.16 1.88 ±0.12  3.80 ±0.32 2.71 ±0.26 
ABCG8 1.07 ±0.15 1.45 ±0.09  3.19 ±0.26 2.33 ±0.19 
LDL-r 1.01 ±0.06 1.00 ±0.11  0.44 ±0.05 0.58 ±0.10 
LXRa 1.13 ±0.22 0.99 ±0.09  1.31 ±0.23 1.68 ±0.25 
Apo-A1 1.06 ±0.14 1.15 ±0.06  1.10 ±0.15 0.97 ±0.10 
SREBP 1.01 ±0.05 1.07 ±0.07  0.36 ±0.04 0.41 ±0.08 
Fold change of different genes expression (Mean and S.E.M) in the liver of ApoE KO WT and MC1Re/e mice against the 
housekeeping genes (Geo.mean S29 & β-actin).    
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Fig. 6: Cholesterol Transporter Genes Expression Level in the Liver 
Cholesterol transporter genes expression level in the liver of chow and 4wks HFD mice.  
(a) ABCG5 and (b) ABCG8 expression in liver samples of both genotypes and diet groups of mice.   
(**P < 0.01 against WT); (####P < 0.0001 = dietary significance); n=8 per group. 
 
2.3 Cholesterol-Rich Diet Influence the Expression of Cholesterol 
Transporter Genes and Pro-inflammatory Mediators in the Spleen 
and Bone Marrow of Mice 
In the spleen and bone marrow of mice, the expression of cholesterol 
transporter genes was unaffected by the genotype. However, the diet type 
altered the level of cholesterol transporter genes expression in these tissues 
(Supplemental- Fig 1 & 2; Table 4 & 5). Western diet fed mice showed an 
increase in cholesterol transporter gene expression in the spleen and bone 
marrow of both wild type and MC1-Re/e mice. The bone marrow and splenic 
macrophages responded to the increased overload of cholesterol in the 
circulatory system via successive increase in the ABCA1 in bone marrow and 
ABCG1 in spleen. 
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Table 4: Gene Expression in the Spleen of Mice 
Gene 
Chow  High Fat Diet (HFD) 
 
WT 
 
MC1-R
 e/e
 
  
WT 
 
MC1-R
 e/e
 
ABCA1 1.01 ±0.05 1.08 ±0.07  1.10 ±0.15 1.24 ±0.12 
ABCG1 1.01 ±0.06 0.90 ±0.04  1.31 ±0.18 1.33 ±0.10 
CD36 1.04 ±0.11 1.22 ±0.16  0.57 ±0.06 0.79 ±0.07 
SRB-1 1.01 ±0.07 1.09 ±0.13  0.77 ±0.05 0.86 ±0.09 
IL-1β 1.05 ±0.12 0.82 ±0.11  0.76 ±0.15 0.56 ±0.09 
CCL-2 1.10 ±0.18 1.65 ±0.28  0.60 ±0.15 0.48 ±0.14 
VCAM-1 1.04 ±0.11 1.07 ±0.15  0.91 ±0.13 1.10 ±0.19 
Fold change of different genes expression (Mean and S.E.M) in the spleen of ApoE KO WT and MC1Re/e mice against 
the S29 housekeeping gene.   
 
The cholesterol transporters (ABCA1, ABCG1 and CD36) and cytokine (IL1β, 
CCL-2) mRNA expression levels in the spleen of both groups of mice were 
expressed differently between the genotypes, but with no statistical difference 
(Supplemental Fig. 1 & 2). However, the diet type seems to play a critical role 
in the expression level of these cholesterol transporter and cytokine genes that 
are being expressed (Supplemental - Fig.1a, b, c & d). In a similar pattern as 
in the spleen, the bone marrow expression of cholesterol transporter genes and 
scavenger receptors did not show any significant differences between the 
genotypes (Supplemental - Fig.2a, b, c & d). This outcome also translates 
similarly to the expression of IL1β and CCL-2 in the spleen, where the 
observable differences are seen in the diet and not in the genotype 
(Supplemental Fig.1c & d).  
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Table 5: Gene Expression of Cholesterol Transporters Genes in the Bone Marrow of 
Mice 
Gene 
Chow  High Fat Diet (HFD) 
 
WT 
 
MC1-R
 e/e
 
  
WT 
 
MC1-R
 e/e
 
ABCA1 1.04 ±0.12 1.33 ±0.14  5.12 ±0.42 4.00 ±0.67 
ABCG1 1.03 ±0.09 1.14 ±0.13  1.64 ±0.27 1.12 ±0.06 
CD36 1.15 ±0.24 1.66 ±0.43  3.65 ±0.31 3.93 ±0.67 
SRA-1 1.06 ±0.13 1.36 ±0.17  1.09 ±0.17 0.96 ±0.17 
SRB-1 1.02 ±0.08 0.90 ±0.06  1.52 ±0.09 1.32 ±0.16 
Fold change of different genes expression (Mean and S.E.M) in the bone marrow of ApoE KO WT and MC1Re/e mice 
against the housekeeping genes (Geo.mean S29 & β-actin).  
 
2.4 H3-Cholesterol Absorption into Plasma, Liver and Excretion in 
Feces of Mice via Cholesterol Efflux Mechanism 
 
The in-vivo cholesterol efflux assay investigation was designed to expatiate on 
the level and distribution of free cholesterol in tissues such as liver, plasma and 
feces in both genotypes. The aim of this experiment was to measure the 
efficiency of cholesterol efflux from H3-cholesterol loaded macrophages 
between the genotypes. Differentiated bone marrow-derived macrophages 
(BMDM) from normal ApoE-/- WT mice were loaded with H3-cholesterol and 
injected intraperitoneally into the ApoE-/- WT and ApoE-/- MC1-Re/e yellow mice. 
After 24 to 48hours, tritiated cholesterol level in the collected plasma, liver and 
feces was measured in a liquid scintillation counter. The mice used in this 
experiment were on normal chow diet.  
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 Fig. 7: H3-Cholesterol Quantification in Plasma, Liver and Feces of Mice 
Amount of H3-cholesterol in liver, feces and plasma of WT and MC1R deficient mice after 24 to 48hrs of 
macrophage ip injection. 
 
The graphs show that the tritiated cholesterol was absorbed in the blood, 
transported to the liver and eventually expelled via feces after 24 and 48 hours. 
However, there was no major difference between the genotypes in this regard.  
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3.  DISCUSSION 
This study was aimed at examining the effects of MC1-R deficiency on 
cholesterol transporter genes in mice that are prone to developing 
atherosclerosis, namely the ApoE-/- mice. We investigated the expression of 
these genes, in addition to inflammatory and stability genes in yellow recessive 
MC1-R deficient (MC1-Re/e) and their littermate black wild type mice of ApoE-/- 
background. Both groups of mice had dietary sub-groups of chow and high fat 
diet (4 weeks HFD).  
We observed in this study, that important cholesterol carrier genes – ABCA1 
and ABCG1 were less expressed in the aorta of MC1-Re/e mice relatively to the 
wild type mice (Fig. 4a & b). A similar event was noted in the levels of ABCG5 
and ABCG8 transporter genes in the liver, when mice were exposed to HFD for 
4 weeks. Thus, we can conclude that MC1-R has an impact on the expression 
of cholesterol transporter genes, which in turn, may affect the transportation of 
cholesterol within the tissues and consequently, contribute to the inflammatory 
process preceding atheroma buildup in aorta. The role of ABCA1 and ABCG1 is 
well documented in the initiation of reverse cholesterol transportation. A recent 
study by Rinne et al supported this finding, when MC1-R was activated by MC1-
R agonists in ApoE-/- mice (Rinne et al; 2017). The macrophages were hindered 
from excess cholesterol accumulation and foam cell development following the 
administration of MC1-R agents. The decrease expression of ABCA1 and 
ABCG1 mRNA in the aorta of chow and high fat diet mice (Fig. 4a & b) was 
likely due to lower biological effect of these genes, when MC1-R expression is 
deficient. Hence, cholesterol efflux, a counter regulatory mechanism against the 
formation of foam cell is in turn affected. Another important contributing factor to 
foam cell development in the aorta is the expression of scavenger receptor 
CD36. Although in this experiment, the expression of CD36 mRNA (Fig.4c) in 
MC1-Re/e mice was not significantly changed relatively to the ApoE-/- wild type, 
previous experiment indicates that CD36 was down-regulated when MC1-R was 
activated (Rinne et al; 2017). Interestingly, we saw a slight increase in CD36 
expression in MC1-Re/e mice in the chow diet fed mice (Fig.4c), but this did not 
reflect in the 4 weeks HFD fed mice.  
21 
 
ABCA1 and ABCG1 transportation of cholesterol to HDL and ApoA-I in the 
aorta of the MC1-Re/e mice may have been impaired based on our results from 
this experiment. The spontaneous deletion of MC1-R in these yellow recessive 
mice may have affected the function of the cholesterol transporters (ABCA1 and 
ABCG1) in transporting cholesterol laden LDL from the plaque in the arterial 
wall to the liver. This outcome second the conclusion of a recent investigation, 
which concluded that the activation of MC1-R agonist in macrophages leads to 
reduction in oxLDL uptake via down regulation of CD36 cell surface expression 
and promote the process of reverse cholesterol transportation by increasing 
ABCA1 and ABCG1 expression (Rinne et al; 2017). The biological mechanism 
between MC1-R deficiency and the down-regulation of cholesterol transporter 
genes is not fully understood yet.  
The activation of MC1-R by endogenous α-MSH through cAMP dependent 
pathway results in the inhibition of pro-inflammatory molecules such as IL- 1β, 
IL-6, NO, TNF-α and INFγ via NF-κB transcription factor  and activation of PKA 
(Horrell et al; 2016). Hypercholesterolaemia allows cholesterol to build up in 
macrophages, the central cells in atherosclerosis disease derived from 
monocytes in circulating blood and other immune cells. This is followed by a 
cascade of inflammatory events that is regulated by the induction of different 
cytokines including interleukins, chemokines and adhesion molecules. The 
expression levels of IL-1β, CCL-2 and P-selectin (CD62P) in the aorta of MC1-R 
deficient mice were significantly reduced. Also, IL-6 mRNA expression level 
followed a similar pattern as IL-1β, CCL-2 and CD62P except the lack of 
significance in expression between the genotypes (Fig 5). The down-regulation 
of these inflammatory players in the aorta was an unexpected finding, since 
hypercholesterolaemia, a pro-inflammatory event, generally increases the 
induction of inflammatory molecules (Stoke et al; 2002). This manifestation 
corresponds to an observation from a previous experiment, where it was 
observed that MC1-Re/e macrophages expressed lower levels of cytokines 
mRNA but still secreted a comparable amount of cytokine proteins (Rinne et al; 
2017). The reason(s) behind this is not completely clear yet. However, we 
speculate that the lower expression level of cytokines mRNA by MC1-R 
deficient mice was stable and biologically active.  
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Melanocortin receptor subtypes other than MC1-R also have a role in anti-
inflammatory regulation in murine macrophages, which could explain the 
reduction of cytokine mRNA expression in MC1-Re/e mice. In Fig 5(e), TGF-β1 
expression was upregulated in the MC1Re/e mice on chow and western diets.  
TGF-β1 cytokine/growth factor has been linked to the pathogenesis of 
atherosclerosis. The inhibition of TGFβ1 signaling tends to inflate 
atherosclerosis progression and induce plaque instability in mice. Mallat et al 
show in their studies that the inhibition of TGF-β1 signaling in ApoE-/- mice 
promoted atherosclerotic lesion development as well as increased inflammatory 
molecules and decreased collagen content. This finding suggests a protective 
role by TGF-β1 in atherosclerosis. TGF-β1 acts in cell cycle regulation and 
apoptosis in different types of cells including smooth muscle and endothelial 
cells. It also functions as an anti-inflammatory cytokine by attenuating the 
cytokine-regulated release of chemokines and adhesion molecules (Vodovotz et 
al; 1993). The atheroprotective role of TGF-β is linked to its deactivating effects 
on macrophages and T-lymphocytes and is unrelated to its cell differentiation 
effects on smooth muscle cells (Mallat et al; 2001). We observed in this 
experiment (Fig 5e), an upregulation of TGF-β1 mRNA in MC1-Re/e mice in both 
diet groups. The possible physiological reason of this outcome is not well 
understood. However, TGF-β has anti-inflammatory effects via the reduction of 
cytokine-induced expression of chemokines and adhesion molecules.  
ABCG5 and ABCG8 promote the excretion of cholesterol into the gut lumen and 
bile, since they are exclusively expressed in the intestines and liver (Berge et al; 
2000). These cholesterol transporters are co-expressed to traffic cholesterol 
from the endoplasmic reticulum site of synthesis in hepatocytes. Although the 
molecular mechanism of ABCG5/G8 cholesterol translocation is not clear yet, 
the heterodimers show ATPase activity and interact with sterols probably using 
this energy to translocate the sterol across the membrane (Muller et al; 2006). 
In mice, the absence of these two transporter genes resulted in reduced 
cholesterol excretion into bile, while in transgenic mice, an enhanced biliary 
secretion of cholesterol was observed as well as a reduction in the amount of 
dietary sterol absorbed (Yu et al; 2002). In an in vitro condition, Vrins and co-
workers (Vrins et al 2007) show that cells expressing ABCG5 and ABCG8 
transporters promote the efflux of cholesterol into bile acids.  
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ABCG5 and ABCG8 cholesterol transporter gene expression was reduced in 
the liver of MC1-Re/e mice relative to the ApoE-/- wild type after 4 weeks on 
western diet (Fig 6a and b). The down-regulation of ABCG5 and ABCG8 was 
not observed with chow diet condition. Mice on normal diet express similar level 
of mRNA for both ABCG5 and ABCG8 transporters. The level of cholesterol in 
the system probably mediates the level of expression of ABCG5 and ABCG8. 
This finding suggests a probable link in the physiological function between 
MC1-R and ABCG5 and ABCG8 cholesterol transporter genes. In a previous 
study on the roles of ABCG5 and ABCG8 role in biliary cholesterol secretion, 
biliary cholesterol was substantially lower in G5G8-/- mice compare to wild type 
mice and only increased modestly when cholesterol-rich diet was given (Yu et 
al; 2002). This result stresses the important role of these two cholesterol 
transporter genes in hepatobiliary cholesterol transportation. In addition, 
ABCG5 and ABCG8 expression was found to prevent against sterol 
accumulation in the liver and intestine of mice as well as to mediate 
extrahepatic cholesterol efflux (Jin et al; 2015).  
An overload of systemic cholesterol can result in the accumulation of 
cholesterol as well as macrophage mediated inflammation.  Cholesterol efflux 
assay helps to quantify the rate at which macrophages efflux cholesterol. The 
cells ability to maintain this efflux as well as the capacity of plasma to accept the 
cholesterol being released from the cells can be measured by this assay. 
Essentially, cholesterol efflux assay demonstrates how a treatment of genetic 
manipulation affects cholesterol efflux capacity and how the plasma capacity to 
accept cholesterol is altered by a treatment or disease.  Figure 7 (cholesterol 
efflux assay) shows that the tritium labelled cholesterol loaded into 
macrophages was successfully accepted into the plasma of both wildtype and 
MC1-Re/e mice and transported into the liver. The radioactive H3-cholesterol was 
transported to the liver, where it was processed and excreted via feces. MC1-
Re/e mice appeared to excrete slightly more radioactive cholesterol after 24 
hours of H3-cholesterol injection, but this has no statistical significant between 
the genotypes.  
This finding could explain the lack of difference in tritiated cholesterol efflux was 
as a result of no difference in expression level of ABCG5 and ABCG8 in the 
liver of chow-fed mice (Fig 6a & b).  
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There was no difference in the level of tritiated cholesterol. This may reflect 
efflux between the tissues or plsma (Figure 7). However, if these mice were fed 
with western diet, the outcome may have been different due to increase dietary 
cholesterol in the plasma. Further experiment vis-à-vis cholesterol efflux using 
HFD mice will be required to analyse any bearing that diet type may have in this 
assay. 
The ApoE-/- mice model used in this investigation represent a widely used 
method in atherosclerosis research. This model allows the spontaneous 
development of atherosclerotic lesions even when mice are fed normal chow 
diet. In addition to this, feeding the mice with HFD also ensures a rapid buildup 
of cholesterol in the plasma. Perhaps, the addition of an 8 and/or 12 weeks 
HFD fed group of mice could have shown more pathological manifestation in 
the tissues analysed in this experiment and may also have impacted the 
expression level of cholesterol transporter genes. Atherosclerosis is a serious 
risk factor to CVDs. A number of treatments for CVDs are available today 
including surgery (e.g. coronary artery bypass). However, a non-invasive 
pharmacological therapy will be a preferred choice for the treatment of early 
atherosclerosis. The treatment of CVDs has had a positive breakthrough with 
the discovery of statins, which reduce blood cholesterol levels. However, other 
associative conditions and the underlying pathology still lack a concrete 
treatment, creating a demand for further research interest.  
 
In conclusion, this investigation reveals that cholesterol transporter genes were 
downregulated in MC1-Re/e mice aorta and liver, an effect exacerbated with diet 
rich in high fat. The macrophages contained in the plaques of the MC1-R 
deficient mice may have reduced capability of cholesterol efflux hence 
hampering the process of RCT. The plaques formed in the aorta of this group 
may also be more vulnerable and thus, unstable as a result of reduced 
expression of Col3A1 and αSMA mRNA. The outcomes of this investigation 
couple with results from previous studies by our group showing that MC1-R 
activation beneficially modifies the phenotype of atherosclerotic plaques.  
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This investigation was part of a bigger project and will be followed by a 
complementary study on plaque phenotyping, which will involve analyzing the 
impact of MC1-R deficiency on plaque size. A further study on the role of MC1-
R on cholesterol homeostasis and trafficking in bigger mammals could proof a 
potential pharmacological therapy to ameliorate the advancement of atheroma 
in human atherosclerosis.  
 
 
4.  MATERIALS AND METHODS
4.1 Animals and Tissue Extraction 
ApoE-/- C57B/J6 (black) and yellow MC1-Re/e were cross-bred to generate ApoE 
-/- and ApoE-/- MC1-Re/e. CO2 asphyxiation was used to sacrifice the mice. After 
euthanasia, samples from the aorta, liver, spleen and bone marrow were 
extracted and stored at -70 oC before further processing.  
During this study, the welfare, health and quality of life of the mice were 
ensured. Mice had free access to the appropriate diet. All animal experiments 
were approved by the local Ethics committees (Animal Experiment Board in 
Finland, License Number: ESAVI-438 /04.10.03/2012) and conducted in 
accordance with the institutional and national guidelines for the care and use of 
laboratory animals. 
 
4.2 RNA Extraction 
Qiazol reagent (500 µL per 50 mg of tissue) was added to tissue in 2 mL 
eppendorf tubes and homogenised. 100 µL chloroform per 500 µL of Qiazol 
reagent was added and incubated at room temperature (RT) for 5 min. Samples 
were centrifuged at 12 000 x g (rcf) for 15 min at +4 oC and the clear upper 
phase was carefully pipetted into a 1.5 mL eppendorf tube. Then 250 µL of 
isopropanol (per 500 µL Qiazol used) was added to the mixture, vortexed and 
incubated at RT for 10 min. Samples were centrifuged at 12 000 x g (rcf) for 10 
min at +4 oC. The supernatant was removed and 500 µL of 75% ethanol was 
added to the pellet, vortexed and centrifuged at 7500 x g for 5 min at +4 oC.  
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The supernatant was decanted and the pellet was allowed to air-dry for about 
10 min in RT after which it was dissolved in RNAse free water for RNA 
concentration measurement with BioSpec-nano Spectrophotometer. Samples 
were stored at -70 oC until cDNA conversion. 
4.3 cDNA Conversion 
cDNA reverse transcription of the RNA samples was carried out with cDNA 
TAKARA PrimeScript RT Kit. The RNA sample was pipetted into small PCR 
eppendorf tubes and the master mix was added to the mixture. Samples were 
slightly centrifuged to get mixture at the bottom of the tube before setting in a 
thermal cycler (Applied Bioscience 2720) with the setting below: 
 
 Step 1 Step 2 Step 3 
Temperature (°C) 37 95 4 
Time (min) 60 5 ∞ 
 
The resultant cDNA was stored at -20 °C after the DNA amplification was 
completed. 
 
4.4 Quantitative RT-PCR 
DNA master mix for RT-PCR was prepared for each specific gene 
(housekeeping, cholesterol transporter, cytokines or stability genes) to run from 
their respective reverse and forward primers (Ambion), nuclease free water and 
SYBR green dye on ice. S29 and/or β-actin housekeeping genes were readily 
expressed in mice’ liver, spleen and bone marrow, while S29 and HPRT 
expressed and stable in mice aorta. 3 µL of the cDNA sample (3 ng/µL) was 
pipetted in duplicate into a 96 PCR well plate on ice. 17 µL of DNA mix was 
added into each well and the plate was sealed with an adhesive film before 
setting the plate into a RT-PCR machine and with the following settings; 
enzyme activation 95 °C, 3:00min; denature 95 °C, 0:03min; anneal 60 °C, 
0:27min. Dissociation stage was added to the setting and ran to obtain Ct-value 
readings in an Applied Bioscience – 7300 Real Time PCR System. The Ct-
values obtained from the qPCR analysis is a relative quantification of 
expression of the target gene(s). 
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Target gene mRNA expression levels were analysed with Ms Excel package 
and normalized to the geometrical mean of ribosomal protein S29 and β–actin 
or HPRT using the comparative ΔCt method and are presented as relative 
transcript levels (2-ΔΔCt). 
 
4.5 In-vivo Cholesterol Efflux Assay:  
4.5.1 Macrophage Cell Culture and 3H-Cholesterol Labelling 
Step 1 (In-vitro Phase): Bone marrow cells were isolated from the femurs and 
tibiae of ApoE-/- mice and differentiated macrophages in M-CSF supplemented 
IMDM-high medium for 7 days. The cells were thereafter loaded with 3H-
cholesterol (5 µCi/mL) and AcLDL (30 µg/mL) in complete medium for 24 hours. 
Cells were washed twice with pre-warmed PBS and equilibrated with IMDM-
high glucose medium containing 0.2% BSA for 4 hours.  
The cells were further washed with pre-warmed PBS twice before detaching 
with EDTA-solution and re-suspended in IMDM medium (target cell amount 10 
million/mL). 
A small aliquot (50 µL) of the cell suspension was taken for LSC counting to 
estimate the total radioactivity to be injected 
 
Step 2 (In-vivo Phase): 300 – 400 µL of cells suspension (containing about 2-3 
million cells, and 300000 dpm in PBS) was injected into each mouse 
intraperitoneally (WT and MC1-Re/e). Blood, feces, gallbladders and livers 
samples were collected for radioactivity (cholesterol) measurement after 24-48 
hours post-injection.  
*** Step 1 was conducted in collaboration with Maija Hollmen and Miro Viitala 
from Medicity Laboratory, Turku. 
 
4.6 Radioactivity Measurements with Scintillation Counter 
4.6.1 Plasma 
Blood samples were collected into EDTA-coated tubes and then centrifuged at 
4000 rpm for 10 min and the resulting plasma fractions were collected into 
separate tubes. An aliquot (100 µL) of the plasma was transferred into LSC tube 
and 4 mL of Optiphase Hisafe 3 LSC cocktail was added.  
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Samples were mix and allowed to stand for 60 min RT before measuring in a 
liquid scintillation counter (WALLAC 1410 LSC).  
 
4.6.2 Liver 
The whole liver was harvested, weighed and approximately 50 mg piece was 
transferred into a 20 mL scintillation vial. 1 mL SOLVABLE (Perkin Elmer) was 
added and the tube was heated in an incubator at 50 - 60 °C for 60 min. Sample 
was cooled to RT and 0.2 mL of 30% H2O2 in two aliquots of 0.1 mL was added 
and then the tubes were transferred to the incubator (50 °C) for 30 min to 
complete decolourisation. 12 mL of LSC cocktail was added to sample then 
allowed to temperature and light adapt for at least one hour before counting.  
 
4.6.3 Feces 
Feces were carefully collected from the cages and weighed (wet and dry). 
Thereafter, 0.1 mL water was added to 20 mg of dried feces and rehydrated for 
30 min in a 20 mL vial. 1.0 mL of SOLVABLE was added and incubated at 50 
°C for 2 hours followed by the addition of 1.0 mL of isopropanol and incubated 
for 2 hours at 50 °C. 30% H2O2 (0.2 mL) was added dropwise and allowed to 
stand for 15 to 30 minutes at RT. Samples were transferred into 50 °C incubator 
for 1 hour and left to cool to RT afterwards. 16 mL of LSC cocktail was added to 
the sample vial. The samples were allowed to temperature and light adapt for 1 
hour before counting. 
 
4.7 Statistics 
Ct values from RT-PCR reactions were transferred unto Excel file for analysis. 
Student's t-test was used to compare two different groups (normal distributed 
data) and for the comparison of multiple groups, two-way ANOVA was applied 
on a GraphPad Prism (GraphPad Prism 6 software) program to assess 
statistical differences between genotype and dietary groups for each target 
genes and housekeeping genes. For H3-cholesterol radioactivity data, student’s 
t-test (two-tailed) and Mann Whitney U test was used to determine statistical 
significance. Data are expressed as means ± SEM and statistical significance 
for all comparisons is assigned at p<0.05 
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6.  ABBREVIATIONS LIST 
α-MSH – alpha melanocyte stimulating hormones 
ABC – ATP binding cassette transporter 
ACE Inhibitors - Angiotensin-Converting-Enzyme Inhibitors 
ACTH – adrenocorticotropic hormone 
AGRP – agouti related protein 
ApoA – Apolipoprotein A 
ApoB – Apolipoprotein B 
ApoE – Apolipoprotein E 
ARG1 - Arginase 
cAMP – cyclic adenosine monophosphate 
CCL-2 - chemokine ligand 2   
CCR5 - C-C chemokine receptor type 5 
CD206 – Mannose Receptor 
CD62P - P-selectin 
CETP - cholesteryl ester transfer protein  
CHD – Coronary Heart Disease 
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CVD – Cardiovascular Disease 
CX3CR1 - CX3C chemokine receptor 1 
HDL - High-Density Lipoprotein 
HFD – High Fat Diet 
ICAM1 – Intercellular Adhesion Molecule 1 
IDL - Intermediate-Density Lipoprotein  
IL-1 – Interleukin 1 
IHD - Ischaemic Heart Disease 
IP3 – inositol triphosphate 
INFγ – Interferon gamma  
KO – Knock Out 
LDL - Low-Density Lipoprotein 
LDL-r – Low Density Lipoprotein Receptor 
LXRa – Liver X Receptor Alpha 
LXR-RXR - Liver X Receptor–Retinoid X Receptor 
MC1R – Melanocortin-1 Receptor 
MMPs - matrix metalloproteinases 
MYD88 - myeloid differentiation primary response protein 88  
NOS – nitric oxide synthase 
NF-κB - nuclear factor kappa-light-chain-enhancer of activated B cells 
PECAM1 - Platelet Endothelial Cell Adhesion Molecule 1 
PKC - phosphokinase C  
PVD - Peripheral Vascular Disease 
POMC – propopiomelanocortin  
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qPCR – Quantitative PCR 
RT - Room Temperature 
RCT - reverse cholesterol transportation  
SR-BI - scavenger receptor class B type I  
SREBP - Sterol Regulatory Element-Binding Proteins 
TGFβ1 – Transforming growth factor beta 
TNF-α - Tumour necrosis factor alpha 
TLR - Toll-like receptor  
VCAM-1 - vascular cell adhesion molecule-1  
VLDL - Very Low Density Lipoprotein
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Supplemental Fig. 1: Cholesterol Transporters and Cytokines Gene in the Spleen of Mice 
Cholesterol transporters and cytokines gene expression in the spleen of chow and 4WKs HFD mice. 
(a) ABCG1 (b) CD36 (c) IL-1β and, (d) CCL-2 mRNA expression in spleen samples of both 
genotypes and diet groups of mice.   
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(# P < 0.05; ## P < 0.01; ### P < 0.001= dietary significance); n=8 per group. 
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Supplemental Fig. 2: Cholesterol Transporters and Scavenger Receptors in the Bone Marrow 
Cholesterol transporters and scavenger receptor gene expression in the bone marrow of chow and 4wks 
HFD mice. (a) ABCA1 (b) ABCG1 (c) CD36 and, (d) SR-A1 mRNA expression in bone marrow samples of 
both genotypes and diet groups of mice.   
(#### P < 0.0001= dietary significance); n=8 per group. 
 
